Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 16/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.51 |
| ▸ | F2 | P00734 | 1/20 | 0.51 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.51 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.47 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.42 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15065018 | 1.00 | F10 (0.66) | F10CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL30146333 | 1.00 | F10 (0.66) | F10CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL78772 | 1.00 | F10 (0.66) | F10CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL29446947 | 1.00 | F10 (0.66) | F10CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL29651806 | 1.00 | F10 (0.66) | F10CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL15857655 | 0.92 | F10 (0.56) | F10CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL11934594 | 0.89 | F10 (0.52) | F10CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL1160974 | 0.89 | F10 (0.54) | F10CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL2994083 | 0.87 | F10 (0.53) | F10 | |
| SCHEMBL19338281 | 0.85 | F10 (0.51) | F10CYP1A2CYP2C9CYP2C19CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140378682-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING RIVAROXABAN | CADILA HEALTHCARE LIMITED (IN) | 2014-12-25 | — | — | US | claimed |
| EP-2616466-A2 | PROCESS FOR DETERMINING THE SUITABILITY FOR DISTRIBUTION OF A BATCH OF A THIOPHENE-2-CARBOXAMIDE DERIVATIVE | Medichem, S.A. (ES) | 2013-07-24 | — | — | EP | claimed |
| WO-2013098833-A2 | PROCESSES AND INTERMEDIATES FOR PREPARING RIVAROXABAN | CADILA HEALTHCARE LIMITED (IN) | 2013-07-04 | — | — | WO | claimed |
| WO-2012035057-A2 | PROCESS FOR DETERMINING THE SUITABILITY FOR DISTRIBUTION OF A BATCH OF A THIOPHENE-2-CARBOXAMIDE DERIVATIVE | MEDICHEM S.A. (ES) | 2012-03-22 | — | — | WO | claimed |
| EP-2459555-B1 | PROCESSES FOR CRYSTALLIZATION OF RIVAROXABAN | KRKA D D NOVO MESTO (SI) | 2021-11-03 | — | — | EP | disclosed |
| WO-2019163731-A1 | PRODUCTION METHOD FOR OXAZOLIDINONE COMPOUND | 住友化学株式会社 | 2019-08-29 | — | — | WO | disclosed |
| EP-2705028-B1 | PROCESS FOR THE PREPARATION OF A RIVAROXABAN AND INTERMEDIATES FORMED IN SAID PROCESS | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 2019-08-21 | — | — | EP | disclosed |
| US-9663505-B2 | Process for the preparation of rivaroxaban | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2017-05-30 | — | — | US | disclosed |
| US-9663505-B2 | Process for the preparation of rivaroxaban | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2017-05-30 | — | — | US | disclosed |
| CN-105085370-B | (S)-1-halo-2-[2-(1,3-dioxo-isoindol)yl]ethyl chloroformate and preparation method thereof | 北大方正集团有限公司 | 2017-04-12 | — | — | CN | disclosed |
| EP-2837628-B1 | METHOD FOR PREPARING RIVAROXABAN INTERMEDIATE | CHINA NAT MEDICINES GUORUI PHARMACEUTICAL CO LTD (CN) | 2016-11-30 | — | — | EP | disclosed |
| WO-2015198259-A1 | PROCESS FOR THE SYNTHESIS OF RIVAROXABAN AND INTERMEDIATE FOR THE PRODUCTION THEREOF | ERREGIERRE S.P.A. (IT) | 2015-12-30 | — | — | WO | disclosed |
| WO-2013098833-A2 | PROCESSES AND INTERMEDIATES FOR PREPARING RIVAROXABAN | CADILA HEALTHCARE LIMITED (IN) | 2013-07-04 | — | — | WO | disclosed |
| WO-2013046211-A1 | PROCESSES FOR THE PREPARATION OF 5-CHLORO-N-({(5S)-2-OXO-3-[4-(3-OXO-4-MORPHOLINYL) PHENYL]-1,3-OXAZOLIDIN-5-YL}METHYL)-2-THIOPHENE-CARBOXAMIDE AND INTERMEDIATES THEREOF | SYMED LABS LIMITED (IN) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013027225-A1 | PROCESSES FOR THE PREPARATION OF 4-{4-[5(S)-(AMINOMETHYL)-2-OXO-1,3-OXAZOLIDIN-3-YL]PHENYL} MORPHOLIN-3-ONE | SYMED LABS LIMITED (IN) | 2013-02-28 | — | — | WO | disclosed |
| EP-2459555-A1 | PROCESSES FOR CRYSTALLIZATION OF RIVAROXABAN | KRKA, D.D., Novo Mesto (SI) | 2012-06-06 | — | — | EP | disclosed |
| WO-2012035057-A2 | PROCESS FOR DETERMINING THE SUITABILITY FOR DISTRIBUTION OF A BATCH OF A THIOPHENE-2-CARBOXAMIDE DERIVATIVE | MEDICHEM S.A. (ES) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012032533-A2 | PROCESSES FOR THE PREPARATION OF 4-{4-[5(S)-(AMINOMETHYL)-2-OXO-1,3-OXAZOLIDIN-3-YL]PHENYL} MORPHOLIN-3-ONE | SYMED LABS LIMITED (IN) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012032533-A2 | PROCESSES FOR THE PREPARATION OF 4-{4-[5(S)-(AMINOMETHYL)-2-OXO-1,3-OXAZOLIDIN-3-YL]PHENYL} MORPHOLIN-3-ONE | SYMED LABS LIMITED (IN) | 2012-03-15 | — | — | WO | disclosed |
| WO-2011012321-A1 | PROCESSES FOR CRYSTALLIZATION OF RIVAROXABAN | KRKA, D.D., NOVO MESTO (SI) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378682-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING RIVAROXABAN | VKORC1, VKORC1L1, F2 | F10 11/4885CYP1A2 16/4885CYP2C9 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.